[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-coronary-syndrome-acs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-coronary-syndrome-acs":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,49,79,110,136,170,206,238,262,290,312],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100627856","efficacy-of-transcutaneous-auricular-vagus-nerve-stimulation-on-alleviating-major-depressive-disorder-in-patients-with-acute-coronary-syndrome-after-percutaneous-coronary-interventiona-prospective-double-blindrandomized-controlled-study-100627856",false,"NCT07454070","Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation on Alleviating Major Depressive Disorder in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention:A Prospective, Double-Blind,Randomized Controlled Study","Inclusion Criteria:\n\n* Age ≥18 years\n* Meeting the diagnostic criteria for ACS\n* 14 days to 12 months after successful PCI, with stable vital signs\n* Meeting the diagnostic criteria for depression according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)\n* HAMD-17 score ≥7 and \\\u003C24 (mild-to-moderate depression), with HAMA score \\\u003CHAMD score;\n* Refusal of psychiatric consultation, antidepressant medication, or psychological therapy by the patient or their legal representative after full informed consent\n* Voluntary participation in the study and signing of the informed consent form\n\nExclusion Criteria:\n\n* Severe heart failure (New York Heart Association \\[NYHA\\] class ≥III)\n* Uncontrolled hypertension (systolic blood pressure ≥180 mmHg and diastolic blood pressure ≥110 mmHg)\n* Electrocardiographic abnormalities (first-degree atrioventricular block with PR interval ≥0.20 s, second-degree type II or third-degree atrioventricular block at any time, 24-hour average heart rate ≤50 beats per minute, RR interval ≥3 s) or a history of syncope unrelated to the current ACS\n* Dialysis-dependent patients\n* Previous renal sympathetic denervation or vagal ganglion ablation\n* Expected survival time \\\u003C4 months\n* Pre-PCI diagnosis of severe mental illnesses, including schizophrenia, severe intellectual disability, or substance abuse\n* Current use of antipsychotic medications\n* High suicide risk\n* Pregnant or lactating women\n* Left ear diseases, acute exacerbation of asthma or chronic obstructive pulmonary disease, or other conditions precluding taVNS treatment\n* Implanted cardiac pacemaker, implantable cardioverter-defibrillator (ICD), or other implantable stimulators (e.g., vagus nerve stimulator, deep brain stimulator)","ALL","18 Years",{"count":18,"type":19},120,"ESTIMATED","INTERVENTIONAL",[22],"NA","This is a randomized, controlled study. ACS follow- up patients aged 18 to 80 years old with hemodynamic stability, who are 14 days to 1 year after PCI, are screened through the HAMD score and the HAMA score. Patients with a HAMD score greater than 7 points and a HAMD score higher than that of the HAMA, are included in this study.\n\nPatients were allocated to the active taVNS group or sham taVNS group with a 1:1 ratio. Both groups received the stimulation for 20 minutes each time, twice a day with an 8-week treatment and a 8-week follow-up.\n\nAll treatments were self-administered by the patients at home after they received training from the hospitals.\n\nThe primary observation endpoints include the depression scores of the HAMD. The secondary observation endpoints include the HAMA 、GAD、 response and remission rates of HAMD ，as well as the PCL-C for post-traumatic stress disorder. We also observed the cardiac function indexes measured by echocardiography and the B-type natriuretic peptide .",[25,26,27,28,29,30,31,32],"Depressive Disorder (Per DSM-V Criteria, Mild-to-moderate)","Acute Coronary Syndrome (ACS)","Percutaneous Coronary Intervention (PCI)","Depressive Disorder","Postoperative Psychological Distress","Heart Rate Variability (HRV)","Inflammatory Factors","Randomized Controlled Trial (RCT)",[34,26,35],"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)","Post-Percutaneous Coronary Intervention (PCI) Psychological Distress","RECRUITING","2026-06-14",{"date":39,"type":40},"2026-06-16","ACTUAL",{"date":42,"type":40},"2026-01-06",{"date":44,"type":19},"2026-08-10",{"name":46,"class":47},"Jing Han","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":20,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":48},"100634540","teleheartcr-vs-clinic-based-cardiac-rehabilitation-after-acute-coronary-syndrome-100634540","NCT07541014","TeleheartCR vs. Clinic-Based Cardiac Rehabilitation After Acute Coronary Syndrome","Comparing a Novel Telehealth-enabled Hybrid Cardiac Rehabilitation Program to Clinic-based Cardiac Rehabilitation for Improving Patient Engagement and Functional Outcomes After ACS","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of acute coronary syndrome within the past 12 months\n* Eligible for outpatient cardiac rehabilitation\n* Able to read and speak English or Spanish\n* Resides in New York State\n\nExclusion Criteria:\n\n* Severe medical or psychiatric comorbidities that would prevent safe or adequate participation\n* High risk for adverse exercise-related cardiovascular events\n* Initiation of cardiac rehabilitation prior to enrollment (i.e., \\>1 session completed)\n* Conditions that would interfere with safe or consistent participation in study procedures\n* Home environment or willingness not compatible with safe or adequate participation\n* Not expected to be available for follow-up during the study period\n* Current participation in another interventional clinical trial that may affect study outcomes",{"count":57,"type":19},250,[22],"Cardiac rehabilitation (CR) is an effective evidence-based intervention that improves outcomes in patients with acute coronary syndrome (ACS), but many eligible patients do not complete the program. A hybrid CR intervention that combines telehealth, home-based, and clinic-based components (TeleheartCR) may increase participation by addressing barriers to access while maintaining the functional capacity benefits of traditional CR. The purpose of this study is to conduct a randomized controlled trial comparing TeleheartCR with traditional clinic-based CR in patients with ACS to evaluate differences in program adherence and pre-to-post program change in functional capacity.",[26,61],"Myocardial Infarction",[63,64,65,66,67,68,69],"Cardiac Rehabilitation","Hybrid Cardiac Rehabilitation","Virtual Cardiac Rehabilitation","Implementation Science","Adherence","Functional Capacity","Telehealth","2026-05-30",{"date":72,"type":40},"2026-06-03",{"date":74,"type":40},"2026-05-19",{"date":76,"type":19},"2029-05",{"name":78,"class":47},"Columbia University",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":20,"phases":89,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100637295","phase-3-lpa-lowering-study-of-pelacarsen-tqj230-in-patients-in-the-us-with-elevated-lpa-and-recent-acs-steminstemi---lpafrontiers-pearl-100637295","NCT07625306","Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI\u002FNSTEMI) - Lp(a)FRONTIERS PEARL","A Randomized, Double-blind, Placebo-controlled, Multicenter Study Evaluating the Efficacy, Safety, Tolerability, and Coronary Plaque Effects of Early Pelacarsen (TQJ230) Initiation in Patients in the US With Elevated Lp(a) and Recent Acute Coronary Syndrome","Inclusion Criteria:\n\n* Lp(a) ≥ 150 nmol\u002FL\n* Within 10 days of hospitalization for ACS event and meets all of the following criteria:\n* Clinical syndrome consistent with spontaneous cardiac ischemia\n* Diagnosis of ACS: ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI)\n\nExclusion Criteria:\n\n* Uncontrolled hypertension\n* Heart failure New York Heart Association (NYHA) class IV\n* History of malignancy of any organs\n* History of hemorrhagic stroke or other major bleeding\n* Platelet count ≤ LLN\n* Active liver disease or hepatic dysfunction\n* Significant kidney disease\n* Contraindication for CCTA or severe contrast allergy\n* Pregnant or nursing women\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply","79 Years",{"count":88,"type":19},240,[90],"PHASE3","CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS).",[26],[94,95,26,96,97,98],"Lipoprotein(a)","ASCVD","STEMI","NSTEMI","pelacarsen (TQJ230)","NOT_YET_RECRUITING","2026-05-27",{"date":102,"type":40},"2026-06-04",{"date":104,"type":19},"2026-08-31",{"date":106,"type":19},"2028-12-07",{"name":108,"class":109},"Novartis Pharmaceuticals","INDUSTRY",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":20,"phases":119,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":48},"100598866","ticino-artificial-intelligence-integration-for-occlusion-myocardial-infarction-100598866","NCT07077057","Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction","TITAN-OMI","Inclusion Criteria:\n\n1. Symptoms suspected of ongoing acute myocardial ischemia: Patients presenting with symptoms such as chest pain, dyspnoea, sweating, nausea or vomiting, pain radiating to the shoulder\u002Farm\u002Fjaw\u002Fback, fatigue, or light-headedness\n2. Age: Patients aged 18 years or older.\n3. Informed Consent: Patients able to provide informed consent\n\nExclusion Criteria:\n\n1. Clear diagnosis of ST-segment elevation MI (STEMI) according to managing physicians.\n2. Pregnancy or Lactation.\n3. Legally incompetent to provide informed consent.\n4. Symptoms onset\\>24 hrs prior to clinical presentation.",{"count":118,"type":19},500,[22],"The goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based ECG interpretation tool improves the early diagnosis and treatment of occlusion myocardial infarction (OMI) in adults presenting with suspected acute coronary syndrome (ACS) who do not meet traditional ST-elevation myocardial infarction (STEMI) criteria.\n\nThe main questions it aims to answer are:\n\n1. Does AI-assisted ECG interpretation enable more timely identification and treatment of OMI, as defined by earlier initiation of coronary intervention?\n2. Does AI-assisted diagnosis reduce infarct size, measured by peak high-sensitivity troponin T (hsTnT) levels?\n\nResearchers will compare AI-assisted ECG interpretation to standard care to determine if the AI tool improves clinical outcomes and care timelines.\n\nParticipants will:\n\n1. Present with symptoms suggestive of ACS but without clear STEMI criteria\n2. Be randomized 1:1 to either AI-assisted or standard ECG interpretation\n3. Undergo follow-up assessments for cardiovascular outcomes, including 30-day death, time to treatment of total coronary occlusion, and peak hsTnT levels",[122,26],"Myocardial Infarction (MI)",[124,125,126],"Occlusion Myocardial Infarction","Electrocardiogram","Artificial Intelligence","2026-04-29",{"date":129,"type":40},"2026-05-05",{"date":131,"type":40},"2025-08-23",{"date":133,"type":19},"2027-09",{"name":135,"class":47},"Cardiocentro Ticino",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":20,"phases":147,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":48},"100595896","leave-nothing-behind-study-which-compares-dcb-with-bail-out-brs-versus-brs-strategy-alone-100595896","NCT07038408","Leave Nothing Behind Study Which Compares DCB With Bail Out BRS Versus BRS Strategy Alone","Multi-center, Open-label, Prospective, Randomized Study to Show Long-term Efficacy of DCB Treatment With Bail-out BRS in Comparison to BRS Treatment of De-novo Native Coronary Artery Lesions in a Relatively Young PCI Population.","LNB","Inclusion Criteria:\n\n* Patients aged ≥ 18 years ≤ 68 years\n* Single vessel or multivessel disease with low to moderate complex de-novo native coronary artery lesions up to 30 mm length and reference vessel diameter 2.75-4.0 mm\n* Maximum of 3 target lesions\n* Maximal cumulative lesion length of all treated lesions 80 mm\n* Signed informed consent for participation in the study\n\nExclusion Criteria:\n\n* ST-segment Elevation Myocardial Infarction (STEMI) treatment at index or in the previous 48 hours\n* Severe calcified lesions\n* Bifurcations lesions with planned 2 device strategy\n* Left-Main (LM) disease ≥ 50% diameter stenosis\n* More than 3 target lesions\n* Renal insufficiency with Glomerular Filtration Rate (GFR) \\\u003C 45 ml\u002Fmin\n* Life expectancy less than 1 year\n* Known hypersensitivity or allergy to aspirin or P2Y12 receptor inhibitors\n* Incapable of providing written informed consent\n* Pregnant or breastfeeding women\n* Under judicial protection, tutorship, or curatorship\n* Participation in another trial","68 Years",{"count":146,"type":19},2256,[22],"The goal of this study is to investigate the equivalence in early and long-term efficacy between the two \"Leave nothing behind strategies\" (Drug-Coated Baloon \\[DCB\\] strategy with bail-out BioResorbable Scaffold \\[BRS\\] versus BRS strategy) of de-novo native coronary artery lesions in a relatively young Percutaneous Coronary Intervention (PCI) population, to be more specific, Patients with Chronic Coronary Syndromes (CCS) and Acute Coronary Syndrome (ACS) (Non-ST-segment Elevation Myocardial Infarction \\[NSTEMI\\] and Unstable angina) between 18-68 years of age scheduled for PCI. The main questions aim to answer are:\n\nDCB strategy with bail-out BRS implantation has equivalent clinical outcomes at 12 months compared to BRS strategy? DCB strategy with bail-out BRS implantation has noninferior angiographic in-segment net gain at 13 months compared to BRS strategy? DCB strategy with bail-out BRS implantation has equivalent clinical outcomes at 60 months compared to BRS strategy?\n\nParticipants will be followed at:\n\n1. st FU visit - 1 month (in hospital)\n2. nd FU visit - 6 months (telephone)\n3. rd FU visit - 365 days±15 days (telephone) - 1Y Primary efficacy endpoint\n4. th FU visit - 395 days±15 days (in hospital) co-primary efficacy endpoint for the angiographic substudy\n5. th FU visit - 730 days±30 days (telephone call) - 2Y\n6. th FU visit - 1095 days±30 days (telephone call) - 3Y\n7. th FU visit - 1460 days±30 days (telephone call) - 4Y\n8. th FU visit- 1825 days±30 days (telephone call) - 5Y",[150,151,27,26],"Drug Coated Balloon","Bioresorbable Scaffold",[153,154,155,156,157,158,159,160],"MULTI-CENTER","OPEN-LABEL","PROSPECTIVE","RANDOMIZED STUDY","LONG-TERM EFFICACY OF DCB TREATMENT WITH BAIL-OUT BRS","BRS TREATMENT","DE-NOVO NATIVE CORONARY ARTERY LESIONS","YOUNG PCI POPULATION","2026-04-27",{"date":163,"type":40},"2026-04-30",{"date":165,"type":40},"2026-04-24",{"date":167,"type":19},"2032-03",{"name":169,"class":109},"Ceric Sàrl",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":20,"phases":180,"briefSummary":181,"conditions":182,"keywords":190,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100572699","orbital-atherectomy-vs-intravascular-lithotripsy-for-the-treatment-of-calcified-coronary-nodules-orbit-shock-100572699","NCT06736665","Orbital Atherectomy vs Intravascular Lithotripsy for the Treatment of Calcified Coronary Nodules (ORBIT-SHOCK).","Comparative Efficacy of Orbital Atherectomy and Intravascular Lithotripsy in the Treatment of Calcified Coronary Nodules. The ORBIT-SHOCK Pilot Study.","ORBIT-SHOCK","Inclusion Criteria:\n\n1. Patients aged ≥ 18 years.\n2. Atherosclerotic coronary artery disease with calcified nodules identified by OCT in a native vessel, eligible for percutaneous coronary revascularization.\n3. Clinical presentation of chronic coronary syndrome or acute coronary syndrome without ST elevation\\*.\n4. Distal vessel reference diameters ≥ 2.5 mm and ≤ 4.0 mm. \\* Non-culprit lesions eligible for revascularization in a staged procedure following a ST-elevation myocardial infarction (STEMI) are considered for inclusion.\n\nExclusion Criteria:\n\n1. Culprit lesions in acute coronary syndrome with ST elevation.\n2. Left main disease.\n3. In-stent restenosis lesions.\n4. Critical stenoses where it is not possible to advance the OCT catheter across the lesion after predilation with a balloon of up to 2 mm in diameter.\n5. Lesion involving a bifurcation with a secondary branch diameter ≥2 mm.\n6. Cardiogenic shock.\n7. Patients requiring cardiac surgery or percutaneous valve intervention within three months before or after angioplasty.\n8. Pregnancy.\n9. Life expectancy of less than one year.\n10. Contraindication for the use of appropriate antiplatelet therapy post-revascularization.\n11. Coronary artery disease with an indication for surgical revascularization.\n12. Advanced chronic kidney disease or anatomical characteristics that contraindicate the use of optical coherence tomography.\n13. Inability to obtain informed consent.\n14. Allergy to eggs or soy, contraindicating the use of OA.",{"count":179,"type":19},50,[22],"The ORBIT-SHOCK pilot study is a multicenter, prospective, randomized clinical trial initiated by investigators. It will include patients diagnosed with atherosclerotic coronary artery disease presenting calcified nodules (CN), identified by optical coherence tomography (OCT), causing significant angiographic stenosis and eligible for revascularization through percutaneous coronary intervention (PCI).\n\nPatients will be randomized in a 1:1 ratio to undergo lesion preparation with either orbital atherectomy (OA) or intravascular lithotripsy (IVL).\n\nThe ORBIT-SHOCK pilot study is a multicenter, prospective, randomized clinical trial initiated by investigators. It will include patients diagnosed with atherosclerotic coronary artery disease presenting calcified nodules (CN), identified by optical coherence tomography (OCT), causing significant angiographic stenosis and eligible for revascularization through percutaneous coronary intervention (PCI). Patients will be randomized in a 1:1 ratio to undergo lesion preparation with either orbital atherectomy (OA) or intravascular lithotripsy (IVL).\n\nThe aim of this pilot trial is to compare PCI outcomes and the incidence of adverse events between both techniques.",[183,184,185,186,187,188,27,189,26],"Coronary Arterial Disease (CAD)","Coronary Calcification","Coronary Calcified Nodules","Orbital Atherectomy","Intravascular Lithotripsy","Optical Coherence Tomography (OCT)","Chronic Coronary Syndrome",[191,192,193,194,195,188,27,189,26,176,196],"Coronary arterial disease","Coronary calcification","Coronary calcified nodules","Orbital atherectomy","Intravascular lithotripsy","ORBIT SHOCK","2026-04-26",{"date":163,"type":40},{"date":200,"type":40},"2025-06-12",{"date":202,"type":19},"2027-12",{"name":204,"class":47},"Spanish Society of Cardiology",6,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":20,"phases":215,"briefSummary":216,"conditions":217,"keywords":220,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":48},"100621753","safety-and-efficacy-of-de-escalation-dual-antiplatelet-therapy-after-biofreedom-stenting-in-acs-patients-with-moderate-to-high-ischemic-and-high-bleeding-risk-100621753","NCT07374718","Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk","Optimization and Verification of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy: Safety and Efficacy of De-escalation Dual Antiplatelet Therapy in Moderate-to-high Ischemic Risk and High Bleeding Risk ACS Patients After BioFreedom™ Drug-Coated Coronary Stenting","Inclusion Criteria:\n\n* Aged ≥ 18 years old\n* ACS patients with high bleeding risk (meeting the ARC-HBR criteria)\n* Moderate-to-high ischemic risk (OPT-CAD score ≥ 90)\n* Predicted by the investigator to be able to tolerate 12 months of DAPT\n* Voluntarily participate and sign the informed consent form, and be willing to receive the designated follow-up of this trial at specific time points\n* Coronary artery lesions are primary and in-situ coronary artery lesions\n* Target lesion diameter stenosis ≥ 70% or ≥ 50% (visual estimation) accompanied by evidence of myocardial ischemia\n\nExclusion Criteria:\n\n* Patients with known allergy or contraindication to P2Y12 inhibitors, aspirin, or contrast agents\n* Patients planning to undergo surgical intervention within 12 months\n* Left Ventricular Ejection Fraction (LVEF) \\\u003C 35%\n* Patients with contraindications to PCI\n* Patients with a history of substance abuse (alcohol, cocaine, heroin, etc.), or with an expected life expectancy of less than 1 year\n* Subjects with poor compliance or judged by the investigator to be unsuitable for participating in the study\n* Female patients who are planning to be pregnant or are pregnant\u002Flactating, and male patients planning to impregnate\n* Chronic total occlusion lesions\n* Lesions involving the left main coronary artery\n* Severe calcified and tortuous lesions",{"count":214,"type":19},468,[22],"Patients with acute coronary syndrome (ACS) who have both high ischemic risk and high bleeding risk represent a challenging population following percutaneous coronary intervention (PCI), as prolonged dual antiplatelet therapy (DAPT) may reduce ischemic events but increases bleeding complications.This prospective, multicenter, randomized controlled study evaluates the safety and effectiveness of an optimized PCI and antiplatelet therapy strategy in ACS patients with moderate-to-high ischemic risk and high bleeding risk. Eligible patients will be randomized in a 1:1 ratio to either an experimental strategy consisting of intravascular ultrasound-guided implantation of a polymer-free drug-coated stent followed by one month of DAPT and subsequent single antiplatelet therapy, or a control strategy consisting of angiography-guided implantation of contemporary drug-eluting stents followed by standard 12-month DAPT.The primary hypothesis is that the experimental strategy will reduce the incidence of net adverse clinical events, defined as a composite of ischemic and bleeding outcomes, compared with conventional PCI and prolonged DAPT. Participants will be followed for 12 months after the index procedure.",[26,218,219],"High Bleeding Risk(HBR)","Coronary Artery Disease (CAD)",[221,26,222,27,223,224,225,226,227,228],"Dual Antiplatelet Therapy (DAPT)","High Bleeding Risk (HBR)","Quality Control Indicators","Coronary Revascularization","Real-World Research","Bleeding Events","Ischemic Events","Post-PCI Prognosis","2026-01-20",{"date":231,"type":40},"2026-01-29",{"date":233,"type":19},"2026-03-01",{"date":235,"type":19},"2029-06-30",{"name":237,"class":47},"Shenyang Northern Hospital",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":245,"targetDuration":247,"studyType":248,"phases":4,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":261,"locationsCount":48},"100620223","optimization-and-validation-of-quality-control-indicators-for-coronary-revascularization-based-on-antiplatelet-therapy-100620223","NCT07354828","Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy","Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy: Establishment of a Quality Control Standard System for Coronary Revascularization in Coronary Heart Disease Based on Dual Antiplatelet Therapy (DAPT)","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* Clinically diagnosed with ACS and received implantation of at least one drug-eluting stent (DES)\n* Meets 1 major criterion or 2 minor criteria of the ARC-HBR high-bleeding-risk definition\n* Able to complete the OPT-CAD score calculation\n* Judged by the investigator to tolerate DAPT for at least 12 months\n* Signed the informed consent form\n\nExclusion Criteria:\n\n* Allergy to study medications such as aspirin, clopidogrel, or ticagrelor\n* Occurrence of major ischemic or bleeding events during the current hospitalization\n* Presence of other severe diseases with a life expectancy of less than one year\n* Pregnancy, or women of childbearing potential who plan to become pregnant within one year\n* Current participation in another clinical study and still within its observation period.",{"count":246,"type":19},3500,"12 Months","OBSERVATIONAL","Study Purpose Coronary heart disease (CAD) is a leading global cause of death, with Acute Coronary Syndrome (ACS) as its acute and life-threatening subtype. Percutaneous Coronary Intervention (PCI) plus stent implantation is the first-line treatment for ACS, and post-PCI Dual Antiplatelet Therapy (DAPT, aspirin + P2Y₁₂ inhibitor) is core for thrombosis prevention but increases bleeding risk. Approximately 40% of ACS patients are classified as High Bleeding Risk (HBR). China lacks a unified DAPT quality control system, and the predictive value of the OPT-CAD ischemic risk score for this population remains unvalidated. This study aims to: 1) Evaluate the feasibility and influencing factors of the DAPT quality control system in HBR ACS patients post-PCI; 2) Verify the accuracy of the OPT-CAD score in predicting ischemic risk, providing evidence for personalized treatment.\n\nEligibility Criteria Inclusion Criteria Aged ≥18 years; Diagnosed with ACS and implanted with at least one drug-eluting stent (DES) during PCI; Meets ARC-HBR (Academic Research Consortium for High Bleeding Risk) HBR definition (1 major criterion or 2 minor criteria); Able to complete OPT-CAD scoring; Tolerates 12-month DAPT (physician assessment); Signs informed consent. Exclusion Criteria Allergy to aspirin, clopidogrel, ticagrelor, or other study-related antiplatelet drugs; Severe ischemia or major bleeding during current hospitalization; Terminal illness with life expectancy \\\u003C1 year; Pregnant or planning pregnancy within 1 year; Enrolled in other ongoing clinical studies. Study Process\n\nThis is a multi-center prospective cohort study (we will follow eligible patients over 12 months to collect real-world data without changing their standard care) recruiting 3,500 participants nationwide. Post-enrollment:\n\nReceive 6-12 months of standard DAPT (regimen determined by your physician); Follow-ups at 1 month (±7 days), 3 months (±14 days), 6 months (±30 days), and 12 months (±30 days) post-PCI (via phone or outpatient visit) to collect medication adherence, bleeding\u002Fischemic events, and clinical outcomes; Confidential data collection via a secure Electronic Data Capture (EDC) system. Study Endpoints Primary Endpoints Feasibility of the DAPT quality control system, inter-hospital differences in DAPT use, 6-12 month DAPT completion rate, and impact of DAPT interruption on patient outcomes; Accuracy of the OPT-CAD score in predicting ischemic risk for HBR patients. Secondary Endpoints 12-month bleeding event rates (BARC 1-5 types, including minor bleeding like puncture site bleeding and major bleeding like intracranial hemorrhage); 12-month ischemic event rates (including target lesion failure-cardiac death, target vessel-related myocardial infarction, or target lesion revascularization-all-cause death, ischemic stroke, definite stent thrombosis, etc.); DAPT interruption rate, P2Y₁₂ inhibitor discontinuation rate (≥1 week), and aspirin discontinuation rate (≥1 week).\n\nKey Information for Participants Voluntary participation: You may withdraw anytime without penalty or loss of medical benefits; Confidential data protection: Personal information will be anonymized with a unique study ID; Free study-related assessments and follow-ups; Prompt medical care will be provided for any adverse events. For inquiries, contact the study team at the participating hospital.",[26,222,219],[221,26,222,27,252,223,224,253,225,226,227,254,228],"OPT-CAD Score","Prospective Cohort Study","Medication Adherence","2026-01-12",{"date":257,"type":40},"2026-01-21",{"date":259,"type":19},"2025-12-30",{"date":235,"type":19},{"name":237,"class":47},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":20,"phases":272,"briefSummary":274,"conditions":275,"keywords":278,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":288,"locationsCount":4},"100571649","phase-2-effect-of-olive-leaf-extracts-on-endothelial-dysfunction-in-patients-with-acute-coronary-syndrome-100571649","NCT06723002","Effect of Olive Leaf Extracts on Endothelial Dysfunction in Patients With Acute Coronary Syndrome","Effect of Olive Leaf Extracts on Endothelial Dysfunction and Short-term Outcome in Patients With Acute Coronary Syndrome","ACS_ATHEROLIV","Inclusion Criteria:\n\nAge over 18 years. Patients presenting with ST-segment alterations at rest, including ST elevation, with or without troponin elevation.\n\nPatients who have not undergone surgery or have no additional primary percutaneous coronary intervention (P-PCI) planned within 8 weeks from the initial P-PCI.\n\nPatients who provide informed consent. Patients available for and willing to adhere to follow-up procedures. Patients without significant cognitive impairment. Patients with a life expectancy of at least 2 years.\n\nExclusion Criteria:\n\n* Severe LV hypertrophy (\\>15 mm);\n* Patients with any evidence of inflammatory or malignant disease.\n* Patient having valvular heart disease, pacemaker; cardiogenic shock\n* Patient having any serious non-cardiac disease associated with a life expectancy \\\u003C1 year\n* Patients undergoing surgery within 30 days\n* Patient having gastrointestinal disorder such as Crohn's disease",{"count":271,"type":19},300,[273,90],"PHASE2","the study aims to examine the short-term (30 days) effects of olive leaf extract on endothelial function in patients with acute coronary syndrome (ACS).\n\nThis investigation will be conducted on patients admitted to the emergency department for ACS. All participants will be screened and included within 24 hours post-ACS event and prior to discharge from the emergency department.",[26,276,277],"Reactive Hyperemia","Endothelial Dysfunction",[279,280,281],"acute conary syndrome","endothelial dysfunction","olive leaf extract","2024-12-03",{"date":284,"type":40},"2024-12-09",{"date":286,"type":19},"2024-12-01",{"date":259,"type":19},{"name":289,"class":47},"University of Monastir",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":297,"enrollmentInfo":298,"targetDuration":4,"studyType":20,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":48},"100550607","restore-imaging-an-oct-ivus-imaging-substudy-of-restore-trial-100550607","NCT06449274","RESTORE Imaging: an OCT-IVUS Imaging Substudy of RESTORE Trial","Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque: an OCT-IVUS Imaging Substudy (RESTORE Imaging)","Inclusion Criteria:\n\n1. Subjects must be between 18 and 80 years of age\n2. Subject must present with acute myocardial infarction or unstable angina planned for PCI\n3. Successful stent implantation (i.e., residual stenosis less than 20%) must be done in culprit lesions and any lesions with ischemia evidence (e.g., QFR equal or less than 0.8)\n4. Subject must have at least one native non-culprit lesion with visually estimated stenosis of 40-80% and QFR \\>0.8\n5. Target lesion must have a visually estimated diameter of 2.0-4.0 mm and length of ≤ 50 mm\n6. Target lesion must have any two of the intravascular imaging criteria of PB \\>65%, MLA \\\u003C3.5 mm\\^2 (OCT) or 4.0mm\\^2 (IVUS), FCT \\\u003C75 μm, or maximal lipid arc \\>180°\n7. Subject must provide written informed consent before any study-related procedure\n\nExclusion Criteria:\n\n1. Subject has known hypersensitivity or contraindication to any of the study drugs (including all asprin, P2Y12 inhibitors, one or more components of the study devices, including paclitaxel, etc) that cannot be adequately pre-medicated\n2. Subject is receiving immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.)\n3. Hypotension, shock, or need for mechanical support or intravenous vasopressors;\n4. Creatinine clearance ≤30 ml\u002Fmin\u002F1.73 m\\^2 (as calculated by MDRD formula for estimated GFR)\n5. Left ventricular ejection fraction\\\u003C30% by the most recent imaging test within 30 days before procedure (echo, MRI, contrast left ventriculography or others)\n6. Life expectancy \\\u003C2 years for any\n7. Subject is currently participating in another investigational drug or device clinical study that has not yet completed its primary endpoint\n8. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.\n9. The target lesion is located within 10 mm of the proximal or distal of stent\n10. The target lesion cannot be in the left main coronary artery\n11. The target lesion is located in a bifurcation lesion (i.e., the diameter of the branch vessels is \\>2 mm with \\>50% of stenosis)\n12. The target lesion is located in severe calcification or tortuosity of vessels\n13. The target lesion involved in the ostium of LAD, LCX or RCA (within 3 mm of the ostium)\n14. The target lesion is located within the bypass graft artery","80 Years",{"count":299,"type":19},180,[22],"The objective of this imaging substudy of RESTORE trial is to demonstrate the superiority of drug-coated balloon (DCB) treatment on non-flow limited vulnerable plaque as compared to guideline-directed medical therapy (GDMT) in improving plaque stabilization in patients with acute coronary syndrome.",[26],"2024-07-11",{"date":305,"type":40},"2024-07-15",{"date":307,"type":40},"2024-06-25",{"date":309,"type":19},"2026-06",{"name":311,"class":47},"Harbin Medical University",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":297,"enrollmentInfo":318,"targetDuration":4,"studyType":20,"phases":320,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":331},"100544178","preventive-drug-coated-balloon-angioplasty-in-vulnerable-atherosclerotic-plaque-restore-trial-100544178","NCT06365502","Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial)","A Multicenter, Prospective, Open-label, Controlled, Randomized Trial of Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial)",{"count":319,"type":19},1860,[22],"The objective of this multicenter, prospective, open-label, controlled, randomized trial is to demonstrate the superiority of drug-coated balloon (DCB) treatment on non-flow limited vulnerable plaque as compared to guideline-directed medical therapy (GDMT) in improving clinical cardiovascular outcomes in patients with acute coronary syndrome.",[26],"2024-05-21",{"date":325,"type":40},"2024-05-22",{"date":327,"type":40},"2024-04-16",{"date":329,"type":19},"2030-12",{"name":311,"class":47},18]